Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Dual muscle-liver transduction imposes immune tolerance for muscle transgene engraftment despite preexisting immunity
Laurent Bartolo, Stéphanie Li Chung Tong, Pascal Chappert, Dominique Urbain, Fanny Collaud, Pasqualina Colella, Isabelle Richard, Giuseppe Ronzitti, Jocelyne Demengeot, David A. Gross, Federico Mingozzi, Jean Davoust
Laurent Bartolo, Stéphanie Li Chung Tong, Pascal Chappert, Dominique Urbain, Fanny Collaud, Pasqualina Colella, Isabelle Richard, Giuseppe Ronzitti, Jocelyne Demengeot, David A. Gross, Federico Mingozzi, Jean Davoust
View: Text | PDF
Research Article Immunology

Dual muscle-liver transduction imposes immune tolerance for muscle transgene engraftment despite preexisting immunity

  • Text
  • PDF
Abstract

Immune responses to therapeutic transgenes are a potential hurdle to treat monogenic muscle disorders. These responses result from the neutralizing activity of transgene-specific B cells and cytotoxic T cells recruited upon gene transfer. We explored here how dual muscle-liver expression of a foreign transgene allows muscle transgene engraftment after adenoassociated viral vector delivery. We found in particular that induction of transgene-specific tolerance is imposed by concurrent muscle and liver targeting, resulting in the absence of CD8+ T cell responses to the transgene. This tolerance can be temporally decoupled, because transgene engraftment can be achieved in muscle weeks after liver transduction. Importantly, transgene-specific CD8+ T cell tolerance can be established despite preexisting immunity to the transgene. Whenever preexisting, transgene-specific CD4+ and CD8+ memory T cell responses are present, dual muscle-liver transduction turns polyclonal, transgene-specific CD8+ T cells into typically exhausted T cells with high programmed cell death 1 (PD-1) expression and lack of IFN-γ production. Our results demonstrate that successful transduction of muscle tissue can be achieved through liver-mediated control of humoral and cytotoxic T cell responses, even in the presence of preexisting immunity to the muscle-associated transgene.

Authors

Laurent Bartolo, Stéphanie Li Chung Tong, Pascal Chappert, Dominique Urbain, Fanny Collaud, Pasqualina Colella, Isabelle Richard, Giuseppe Ronzitti, Jocelyne Demengeot, David A. Gross, Federico Mingozzi, Jean Davoust

×

Figure 1

Transgene-specific immune tolerance in muscle is imposed by concurrent liver targeting.

Options: View larger image (or click on image) Download as PowerPoint
Transgene-specific immune tolerance in muscle is imposed by concurrent l...
Male C57BL/6 mice were injected in the left tibialis anterior muscle with 109 viral genomes (vg) of rAAV1 encoding mOVA under the muscle-specific SPc5-12 promotor and injected i.v. with 1 × 1010 vg rAAV8 encoding mOVA under the liver-specific promotor hAAT. Experimental conditions listed correspond to rAAV1/mOVA i.m. injection and to simultaneous injections of rAAV1/mOVA i.m. and rAAV8/mOVA i.v. Lymphocytes were extracted from blood at day 14 and day 28 to analyze OVA-specific CD8+ T cells by Kb/OVA257 tetramer staining and cytometry. (A) Representative dot plots at day 28 and (B) frequencies of CD8+ Kb/OVA257 tetramer+ (tetramer+) in blood gated on CD8+ T cells. (C) Concentration of anti-OVA IgG relative to a control serum in AU. (D) Reverse transcription quantitative PCR (RT-qPCR) performed in muscle at day 29 in the experimental conditions listed. RT-qPCR results are expressed relative to OVA RNA expression in the “i.m. + i.v.” group (see Methods). Each dot represents an individual animal, mean ± SEM (n = 9 mice per group, pooled from 3 independent experiments). **P < 0.01, ****P < 0.0001 (Mann-Whitney test).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts